Pralmorelin

Growth Hormone Secretagogue (GHRP)Rx: PrescriptionCompound: Approved

Also known as: GHRP-2, Growth Hormone-Releasing Peptide-2, KP-102, Macimorelin precursor analog

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Pralmorelin (GHRP-2) is a synthetic growth hormone-releasing hexapeptide approved in Japan as a diagnostic agent to assess GH secretory capacity. It stimulates GH release via GHSR-1a activation and is used in the diagnosis of GH deficiency.

Mechanism of Action

Synthetic hexapeptide that acts as a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR-1a), stimulating pulsatile release of growth hormone from the anterior pituitary gland.

Routes of Administration

IntravenousSubcutaneous

Goals & Uses

  • Anti-aging / GH replacement researchResearchLow
  • Muscle mass and body composition improvementPerformance/Body CompositionLow
  • Increase growth hormone secretionEndocrineModerate
  • Diagnosis of growth hormone deficiencyDiagnosticHigh
  • Appetite stimulationNutritionalLow

Contraindications

  • Hypersensitivity to pralmorelin or excipientsAllergyHigh
  • Active malignancyOncologyHighUse caution or avoid depending on agent and context
  • PregnancyPopulationModeratePotential fetal risk or insufficient safety data
  • Untreated hypothyroidismEndocrineModerate

Adverse Effects

  • FlushingVascularCommonWarmth and redness of the skin
  • NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
  • Elevated cortisol/prolactinEndocrineUncommon
  • Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
  • Transient hypotensionCardiovascularUncommon

Drug Interactions

  • GlucocorticoidsModerate
  • Somatostatin analogs (e.g., octreotide)High
  • Insulin / Hypoglycemic agentsModerate

Population Constraints

  • Pediatric patientsAgeRelative
  • Elderly patientsAgeRelative
  • Obese individualsMetabolicRelative
  • Patients with renal or hepatic impairmentOrgan FunctionRelative

Regulatory Status

  • European UnionUnapprovedNot approved by the EMA; available for research use only.
  • United StatesUnapprovedNot FDA-approved; classified as a research compound in the US. Widely available in gray market as GHRP-2.
  • United KingdomUnapprovedNot approved by the MHRA; no licensed indication in the UK.

Approved in Japan (Kaken Pharmaceutical) as a diagnostic agent for GH deficiency testing. Not approved by the FDA or EMA for therapeutic or diagnostic use. Widely used in research settings as GHRP-2.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack